PER® Chemotherapy Foundation Symposium (CFS) | Conference

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

November 16th 2024

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

November 14th 2024

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

November 14th 2024

Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.

Piecing Together the Proper BTK Usage in CLL

November 13th 2024

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

November 13th 2024

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

42nd Annual CFS Preview for Medical Oncologists: The Show and After Show

November 7th 2024

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management

November 10th 2023

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Dr Scher on the Importance of Molecular Testing in Prostate Cancer

November 10th 2023

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Reflecting on Advances Made in High-Risk, Low-Grade Prostate Cancer Management

November 10th 2023

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer

November 10th 2023

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer

November 10th 2023

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC

November 10th 2023

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap Syndromes

November 10th 2023

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

Pursuit of Effective Agents Continues in Multiple Types of Sarcomas

November 10th 2023

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

Unique Molecular Profiles of Biliary Tract Cancers Drive Continued Development of Targeted Therapies

November 9th 2023

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer

November 9th 2023

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

Markman Underscores Unanswered Questions in Ovarian Cancer Management

November 9th 2023

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm

November 9th 2023

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.